4'-methoxybiphenyl-3-carbonyl chloride | 1392482-17-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4'-methoxybiphenyl-3-carbonyl chloride
• 英文别名: 3-(4-Methoxyphenyl)benzoyl chloride
• CAS: 1392482-17-5
• 化学式: C₁₄H₁₁ClO₂
• 分子量: 246.693
• InChiKey: UPOXNBCAYBOBMF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4'-methoxybiphenyl-3-carbonyl chloride 、 3-(N-(N-tert-butoxycarbonyl-L-leucyl)sulfamoyl)benzeneamine 在 盐酸 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 反应 0.5h， 生成 N-(3-(N-L-leucylsulfamoyl)phenyl)-4'-methoxy-(1,1'-biphenyl)-3-carboxamide
  参考文献：
  名称：

  N-（3-氨磺酰基苯基）酰胺作为布氏锥虫亮氨酰tRNA合成酶抑制剂的设计与合成

  摘要：

  原生动物寄生虫布氏锥虫（T. brucei）引起人类非洲锥虫病（HAT），这是热带地区的一种致命且被忽视的疾病，因此迫切需要新的治疗方法。亮氨酰tRNA合成酶（LeuRS）是开发抗微生物剂的有吸引力的靶标。在这项工作中，我们从受到打击的化合物硫脲ZCL539开始，设计并合成了一系列酰胺，作为有效的布氏布鲁氏菌LeuRS（Tb LeuRS）合成位点抑制剂。最有效的化合物74和91的IC 500.24和0.25μM，比起始命中化合物的效力高700倍。还讨论了结构-活性关系。这些化合物提供了新的脚手架和先导化合物，用于抗锥虫病药物的进一步开发。

  DOI：

  10.1016/j.ejmech.2021.113319
• 作为产物：
  描述：

  3-氰基苯硼酸 在 四(三苯基膦)钯 、 草酰氯 、 sodium carbonate 、 N,N-二甲基甲酰胺 、 potassium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 3.5h， 生成 4'-methoxybiphenyl-3-carbonyl chloride
  参考文献：
  名称：

  Small molecules that regulate zymosan phagocytosis of macrophage through deactivation of Rho GTPases

  摘要：

  Phagocytosis and subsequent degradation of pathogens by macrophages play a pivotal role in host innate immune response to microbial infections. To find small molecule regulators for the investigation of complicated phagocytic process, we screened our in-house chemical library and found chemicals which inhibit phagocytosis of zymosan by macrophages. A representative compound 5a reduced phagocytosis of zymosan in both peritoneal macrophages and RAW264.7 cells in a dose-dependent manner. Treatment of 5a led to downregulate the key regulators of phagocytosis, Rac1, Rac2 and Cdc42, and slightly reduced phosphorylation of Akt by zymosan. Crown Copyright (C) 2012 Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.06.043

文献信息

• Novel and potent small-molecule urotensin II receptor agonists
  作者：Fredrik Lehmann、Erika A. Currier、Bryan Clemons、Lars K. Hansen、Roger Olsson、Uli Hacksell、Kristina Luthman

  DOI：10.1016/j.bmc.2009.04.062

  日期：2009.7

  A series of analogs of the non-peptidic urotensin II receptor agonist N-[1-(4-chlorophenyl)-3-(dimethylamino)propyl]-4-phenylbenzamide (FL104) has been synthesized and evaluated pharmacologically. The enantiomers of the two most potent racemic analogues were obtained from the corresponding diastereomeric mandelic amides. In agreement with previously observed SAR, most of the agonist potency resided

  已经合成了一系列非肽尿紧张素II受体激动剂N- [1-（4-氯苯基）-3-（二甲基氨基）丙基] -4-苯基苯甲酰胺（FL104）的类似物，并进行了药理学评价。两种最有效的外消旋类似物的对映异构体获自相应的非对映体扁桃酰胺。与先前观察到的SAR一致，大多数激动剂效力存在于（S）对映异构体中。新系列中最有效的UII受体激动剂是（S）-N- [3-二甲基氨基-1-（2-萘基丙基）丙基] -4-（4-氯苯基）苯甲酰胺（ 在尿紧张素II处EC 50 = 23 nM受体）。
• 신규 바이페닐―３―카르복스아마이드 유도체 또는 이의 염 및 이를 유효성분으로 함유하는 자가 면역질환 치료 또는 예방용 약학조성물
  申请人：CHUNG ANG University industry Academic Cooperation Foundation 중앙대학교 산학협력단(220040385305) BRN ▼108-82-05979

  公开号：KR101485247B1

  公开（公告）日：2015-01-22

  본 발명은 신규 바이페닐-3-카르복스아마이드 유도체 또는 이의 염 및 이를 유효성분으로 함유하는 자가 면역질환 치료 또는 예방용 약학조성물에 관한 것으로, 상기 바이페닐-3-카르복스아마이드 유도체 또는 이의 염은 대식세포의 탐식작용을 억제하는 효과가 우수하므로 류마티스 관절염 등과 같은 자가 면역질환을 예방 또는 치료할 수 있는 약학적 조성물 또는 면역 억제제로서 유용하게 사용할 수 있다.

  本发明涉及一种新的联苯-3-甲酰胺衍生物或其盐，以及含有该联苯-3-甲酰胺衍生物或其盐作为有效成分的用于治疗或预防自身免疫性疾病的药物组合物，所述联苯-3-甲酰胺衍生物或其盐具有优越的抑制巨噬细胞吞噬作用的效果，因此可用作预防或治疗类风湿关节炎等自身免疫性疾病的药学组合物或免疫抑制剂。
• Iridium(iii) complexes with enhanced film amorphism as guests for efficient orange solution-processed single-layer PhOLEDs with low efficiency roll-off
  作者：Jun Dai、Kaifeng Zhou、Ming Li、Huiqin Sun、Yunqing Chen、Shijian Su、Xuemei Pu、Yan Huang、Zhiyun Lu

  DOI：10.1039/c3dt50834j

  日期：——

  By introducing a phenyl substituent into the meta-site of the phenyl segment of the 2-phenylbenzothiazole ligand, two novel orange iridium(III) complexes, namely, (3Phbt)222Ir(acac) and (3OMePhbt)222Ir(acac), have been synthesized. Compared with their parent compound (bt)222Ir(acac), both of them possess much enhanced thermostability and film amorphism, making them suitable candidates as guests for high performance solution-processed phosphorescent organic light-emitting diodes (PhOLEDs). However, (4Phbt)222Ir(acac) bearing para-phenyl possesses worse processability relative to (bt)222Ir(acac) due to spontaneous crystallization stemming from the intense intermolecular interactions. Single-layer solution-processed PhOLEDs with (3Phbt)222Ir(acac) and (3OMePhbt)222Ir(acac) as guests show peak current efficiency of 17.2 cd A−1 and 15.2 cd A−1, and maximum brightness of 28 270 cd m−2 and 27 900 cd m−2, respectively. Both are greatly improved compared to the devices employing (bt)222Ir(acac) (10.2 cd A−1 and 14 350 cd m−2) and (4Phbt)222Ir(acac) (5.0 cd A−1 and 13 790 cd m−2) as phosphors. Moreover, quite low efficiency roll-off is acquired in these devices at high luminance. The much improved electroluminescence performances of these objective complexes could be mainly attributed to the presence of a rigid phenyl on the appropriate substitution site of the cyclometallate ligand, which leads to improved thermostability with compatible alleviated intermolecular interactions, and consequently enhanced film amorphism.

  通过在 2-苯基苯并噻唑配体苯基段的元位上引入苯基取代基，合成了两种新型橙色铱（III）配合物，即 (3Phbt)222Ir(acac) 和 (3OMePhbt)222Ir(acac)。与母体化合物 (bt)222Ir(acac) 相比，这两种化合物的热稳定性和薄膜非晶性都大大增强，因此适合作为高性能溶液处理磷光有机发光二极管（PhOLED）的客体。然而，与(bt)222Ir(acac)相比，含有对位苯基的(4Phbt)222Ir(acac)具有更差的可加工性，这是因为强烈的分子间相互作用会导致自发结晶。以 (3Phbt)222Ir(acac) 和 (3OMePhbt)222Ir(acac) 为客体的单层溶液加工 PhOLED 的峰值电流效率分别为 17.2 cd A-1 和 15.2 cd A-1，最大亮度分别为 28 270 cd m-2 和 27 900 cd m-2。与采用(bt)222Ir(acac)（10.2 cd A-1 和 14 350 cd m-2）和(4Phbt)222Ir(acac)（5.0 cd A-1 和 13 790 cd m-2）作为荧光粉的器件相比，这两种荧光粉的亮度都有很大提高。此外，这些设备在高亮度下的效率衰减非常低。这些目标配合物的电致发光性能之所以大大提高，主要是由于环金属配体的适当取代位点上存在一个刚性苯基，从而提高了热稳定性，减轻了分子间的相互作用，进而增强了薄膜的非结晶性。